Document Detail


Comparative analysis of cell death induction by cisplatin and 5-FU in human oral squamous and hepatocellular carcinoma cell lines.
MedLine Citation:
PMID:  18383853     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We established the optimal conditions for the induction of cell death by cisplatin (CDDP) and 5-fluorouracil (5-FU) in human oral squamous cell carcinoma (HSC-2, HSC-3, HSC-4) and human hepatocellular carcinoma (HepG2) cell lines. HSC-3 cells were the most sensitive to 48 hours' continuous treatment with CDDP, followed by HepG2, HSC-2 and HSC-4 cells. On the other hand, HSC-4 cells were the most sensitive to 48-hour continuous treatment with 5-FU, followed by HSC-2, HSC-3 and HepG2 cells. CDDP induced internucleosomal DNA fragmentation in HSC-2 and HSC-3 cells, but not in HSC-4 cells, while 5-FU failed to induce internucleosomal DNA fragmentation in all of these cells. The treatment of HSC-2, HSC-3 and HSC-4cells with CDDP for 12 hours (followed by incubation for 36 hours without CDDP) showed comparable magnitude of cytotoxicity and caspase-3 activation with that attained by continuous 48-hour CDDP treatment. On the other hand, the cytotoxicity of 5-FU depended both on the dose and the exposure time. The present study demonstrate that the most effective treatment time is 12 hours for CDDP and much longer for 5-FU in all studied cell lines, underlining the importance of optimizing the treatment time for each chemotherapeutic agent.
Authors:
Masahiko Okamura; Jun Shimada; Hiroshi Sakagami
Related Documents :
10355973 - Pseudovascular squamous cell carcinoma of the uterine cervix: a lesion that may simulat...
478213 - Regeneration of vitamin a deficient rat tracheal epithelium after mild mechanical injur...
21653343 - Development of biochemical specialization and organelle partitioning in the single-cell...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anticancer research     Volume:  28     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:    2008 Jan-Feb
Date Detail:
Created Date:  2008-04-03     Completed Date:  2008-04-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  253-9     Citation Subset:  IM    
Affiliation:
Division of Oral Maxillofacial Surgery, Department of Diagnostic and Therapeutic Sciences, Meikai University School of Dentistry, Sakado, Saitama 350-0283, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antimetabolites, Antineoplastic / pharmacology*
Antineoplastic Agents / pharmacology*
Apoptosis / drug effects*
Carcinoma, Hepatocellular / drug therapy*,  pathology
Carcinoma, Squamous Cell / drug therapy*,  pathology
Caspases / metabolism
Cell Line, Tumor
Cisplatin / pharmacology*
DNA Fragmentation / drug effects
Enzyme Activation
Fluorouracil / pharmacology*
Humans
Isoenzymes
Liver Neoplasms / drug therapy*,  pathology
Mouth Neoplasms / drug therapy*,  pathology
Chemical
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Antineoplastic Agents; 0/Isoenzymes; 15663-27-1/Cisplatin; 51-21-8/Fluorouracil; EC 3.4.22.-/Caspases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Stage-related decorin and versican expression in human laryngeal cancer.
Next Document:  Adhesion to fibronectin induces megakaryocytic differentiation of JAS-REN cells.